This trial tests different versions of an investigational medicine, semaglutide, in up to 260 participants to measure the amount of semaglutide in the blood. Participants take tablets daily for 18 weeks and are randomized to 1 of 4 groups. No food/water 2 hrs before dose & no other meds 14 days prior. Women can't be pregnant/breastfeeding.
1 Primary · 2 Secondary · Reporting Duration: From 0 to 24 hours after dosing on days 70, 98 and 126
Awards & Highlights
4 Treatment Groups
Sequence A: Semaglutide J-Semaglutide C-Semaglutide J
1 of 4
Sequence C: Semglutide J-Semaglutide J-Semaglutide C
1 of 4
Sequence B: Semaglutide C-Semaglutide J-Semaglutide J
1 of 4
Sequence D: Semaglutide J-Semaglutide C-Semaglutide J
1 of 4
260 Total Participants · 4 Treatment Groups
Primary Treatment: Sequence A: Semaglutide J-Semaglutide C-Semaglutide J · No Placebo Group · Phase 1
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Age 18 - 64 · All Participants · 1 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
Frequently Asked Questions
Is the age restriction for participation in this experiment above or below 55 years of age?
"The current study stipulates that participants are between 18 and 64 years old. However, there are 54 trials for younger patients and 370 dedicated to seniors." - Anonymous Online Contributor
What criteria must a person satisfy in order to be accepted into this research?
"To be eligible for this experiment, potential participants must have no underlying health conditions and lie between 18 - 64 years old. In total, there are 260 slots to fill in the trial." - Anonymous Online Contributor
Is the enrollment period for this trial open at present?
"Clinicaltrials.gov states that this particular medical study is no longer enrolling participants, having opened and closed on March 15th and 13th of 2023 respectively. However, there are still 827 other trials actively seeking volunteers at the moment." - Anonymous Online Contributor
Has the FDA sanctioned Sequence A: Semaglutide J-Semaglutide C-Semaglutide J?
"Due to it being a Phase 1 trial, with limited data on efficacy and safety, our group at Power rated Sequence A: Semaglutide J-Semaglutide C-Semaglutide J as having a low level of safety (1 out of 3)." - Anonymous Online Contributor